Health EU increases pressure on vaccine producers

18:30  24 january  2021
18:30  24 january  2021 Source:   dw.com

The most beautiful natural wonders on the planet

  The most beautiful natural wonders on the planet From a multicoloured canyon to a colossal glacier floating on tranquil teal waters, these are the world's most picturesque natural wonders.

Objectives of the EU Vaccine Strategy. Vaccination preparedness in EU countries. This approach will decrease risks for companies while speeding up and increasing manufacturing. Under its vaccines strategy, the Commission has forged agreements with individual vaccine producers on

European Council President Charles Michel, who led a call of EU leaders this week, said Thursday that officials were considering all ideas to try and stop future vaccine delays. "All possible means will be examined to ensure rapid supply, including early distribution to avoid delays," he said.

After the announcement of delays in corona vaccine deliveries, the EU wants to get the manufacturers going. The federal government is preparing for possible attacks on vaccination centers.

Provided by Deutsche Welle © European Union / Xinhua / picture alliance Provided by Deutsche Welle

"We want to ensure that pharmaceutical companies adhere to the contracts that they have signed," said EU Council President Charles Michel (article picture). In order to guarantee this, the European Union could also use "legal means".

Most recently, bottlenecks at the vaccine manufacturers Pfizer and AstraZeneca caused anger in Europe. The British-Swedish company AstraZeneca announced on Friday that it could initially supply the EU with fewer corona vaccine doses than planned. The reason is problems in "a plant in our European supply chain". A week earlier, the American company had informed Pfizer about delays in delivery of the BioNTech vaccine developed in Germany due to renovation work in a plant in Belgium.

What’s Going On with a COVID-19 Vaccine?

  What’s Going On with a COVID-19 Vaccine? Moderna just announced that early data shows its vaccine appears to be 94.5% effective , also based on early data. But don’t book that family reunion for mid-2021 just yet. While it’s certainly news worth celebrating, there are a lot of unknowns about these vaccines and the many others in development—including when they will be widely available. “This news, in my opinion, is a little early,” says Horacio Bach, adjunct professor in the University of British Columbia’s division of infectious diseases, of the Pfizer news last week.

EU vaccines strategy. Global cooperation. The European Commission is participating in the COVAX Facility for equitable access to affordable On 12 November, the European Union announced it will contribute an additional €100 million in grant funding to support the COVAX Facility to secure access

The EU is expected to make a decision by 29 January. So far, the bloc has approved vaccines made by Pfizer (PFE) /BioNTech (BNTX) and Moderna "We insisted on a precise delivery schedule on the basis of which Member States should be planning their vaccination programs, subject to the granting

Impfstoff von BioNTech/Pfizer: weltweit begehrt © Christof STACHE / AFP Vaccine from BioNTech / Pfizer: coveted worldwide

You understand that "obstacles" arise when building production capacities and supply chains, said Michel. But the EU must "roll up its sleeves and fight for it" to find out the exact reasons and to contain them. Pfizer initially announced delivery delays of several weeks. After the EU had "hit the table", it was only about a week.

AstraZeneca's vaccine is not yet approved in the EU. On January 29th, however, the EMA could give the green light.

The EU Commission actually assumed that the member states would be able to vaccinate at least 70 percent of the adult population with the doses it bought by the end of the summer. Michel now admitted that this goal would be difficult to achieve.

COMMENTARY: What scientists look for in COVID-19 clinical trial results

  COMMENTARY: What scientists look for in COVID-19 clinical trial results Alan McGreevy of the University of Winnipeg has some questions you might keep in mind as you read about vaccine studies.However, there is also a lot of vaccine skepticism, as well as questions about how much confidence should be placed in these announcements.

Last month, Pfizer announced that its vaccine – developed alongside German firm BioNTech – had proven to be more than 90 percent effective in giving immunity to trial participants, getting the green light from UK health authorities on Wednesday to begin distribution for widespread use.

Vaccines are safe and save lives. The rapid development of COVID-19 vaccines has people asking questions. Here is an overview of the reactions and side effects you can expect. It is normal to have certain reactions after a vaccination : There may be redness, swelling or pain around the injection site.

"Abstract hazard"

The federal government fears massive attempts to disrupt the corona vaccination campaign. Because of the "large media presence as well as the high dynamic and emotionality" of the topic there is an "abstract risk" for the headquarters of pharmaceutical companies, vaccination centers, vaccine transports and storage facilities, according to a written response from the Federal Ministry of the Interior to a request from the Greens.

So "vaccination opponents, corona skeptics and conspiracy theorists" could try to penetrate the facilities in order to emphasize their protest. "This could be accompanied by escalating damage to property in the buildings. In individual cases, encounters with the employed staff or the vaccine recipients could also lead to criminally relevant physical assaults," according to the Interior Ministry. However, there are no concrete indications of attacks.

Impfzentrum in Berlin: in Gefahr? © Kay Nietfeld / AFP / Getty Images vaccination center in Berlin: in danger?

The Ministry sees a further danger in specific espionage attempts by foreign secret services. "Several alleged research attempts with regard to German vaccine manufacturers have already become known". The risk of cyber attacks must be "classified as high".

wa / nob (afp, dpa, rtr)

Is the COVID-19 Vaccine Safe For Everyone? Here’s Who Should (and Shouldn't) Get It, According to Experts .
Both vaccines have been issued emergency use authorizations by the FDA—but some groups still have questions about the vaccine's safety.It's a monumental accomplishment for science, having not one but two vaccines go through the vaccine development and approval process in less than a year, in order to fight the COVID-19 pandemic. But while many have widely praised the vaccines and the scientists behind them for their rigorous testing through vaccine trials, some still have questions about vaccine safety in specific groups. Here's what you need to know.

usr: 0
This is interesting!